Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study
When Doug Williams exited his role as R&D chief at Biogen a couple of years ago to run his own startup, he made the leap based on the promise that some of the venture players in biotech were buying into a whole new approach to company creation.
Shoestring budgets were being replaced with company launch plans that dwarfed the old VC model. And a traditional focus on one or two assets shifted to a commitment to pricey pipeline construction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.